Evidence map›Paper›PMID 36494221›Full record

ArticleEuropean urology2023

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith and 108 more

Open access · hybridAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  13. Article
  14. ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

118 authors at 20 institutions in 27 countries.

Silke GillessenOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch.
Alberto BossiGenitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France.
Ian D DavisMonash University and Eastern Health, Victoria, Australia.
Johann de BonoThe Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
Karim FizaziInstitut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Nicholas D JamesThe Institute of Cancer Research, London, UK.
Nicolas MottetUniversity Jean Monnet, St Etienne, France.
Neal ShoreCarolina Urologic Research Center, Myrtle Beach, SC, USA; Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, USA.
Eric SmallUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Mathew SmithMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Christopher SweeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Bertrand TombalCliniques universitaires Saint Luc, Brussels, Belgium.
Emmanuel S AntonarakisMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Ana M AparicioDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
Gerhardt AttardUniversity College London Cancer Institute, London, UK.
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anders BjartellDepartment of Urology, Skåne University Hospital, Malmö, Sweden.
Pierre BlanchardDépartement de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Alberto BrigantiUnit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Rob G BristowDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
Muhammad BulbulDivision of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Orazio CaffoDepartment of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
Daniel CastellanoMedical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Elena CastroInstitute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.
Heather H ChengFred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
Kim N ChiBC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Simon ChowdhuryGuys and St Thomas's NHS Foundation Trust, London, UK.
Caroline S ClarkeResearch Department of Primary Care & Population Health, Royal Free Campus, University College London, London, UK.
Noel ClarkeThe Christie and Salford Royal Hospitals, Manchester, UK.
Gedske DaugaardDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Maria De SantisDepartment of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
Ignacio DuranDepartment of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
Ros EelesThe Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Eleni EfstathiouHouston Methodist Cancer Center, Houston, TX, USA.
Jason EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Onyeanunam Ngozi EkekeDepartment of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
Christopher P EvansUniversity of California Davis School of Medicine, Sacramento, CA, USA.
Stefano FantiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Felix Y FengUniversity of California San Francisco, San Francisco, CA, USA.
Valerie FonteyneDepartment of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium.
Nicola FossatiDepartment of Urology, Ospedale Regionale di Lugano, Civico USI - Università della Svizzera Italiana, Lugano, Switzerland.
Mark FrydenbergDepartment of Surgery, Prostate Cancer Research Program, Monash University, Melbourne, Australia; Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
Daniel GeorgeDepartment of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA; Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
Martin GleaveUrological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Gwenaelle GravisDepartment of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
Susan HalabiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Daniel HeinrichDepartment of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Celestia HiganoUniversity of British Columbia, Vancouver, British Columbia, Canada.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Lisa G HorvathChris O'Brien Lifehouse, Camperdown, NSW, Australia; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia.
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Barbara Alicja Jereczek-FossaDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Robert JonesSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre, Singapore.
Pirkko-Liisa Kellokumpu-LehtinenFaculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland; Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland.
Raja B KhauliDepartment of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
Laurence KlotzDivision of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Gero KramerDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Raya LeibowitzOncology Institute, Shamir Medical Center, Be'er Ya'akov, Israel; Faculty of Medicine, Tel-Aviv University, Israel.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; University of Athens Alexandra Hospital, Athens, Greece.
Brandon A MahalDepartment of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA.
Fernando MalufBeneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Joaquin MateoDepartment of Medical Oncology and Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
David MathesonFaculty of Education, Health and Wellbeing, Walsall Campus, Walsall, UK.
Niven MehraDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Axel MerseburgerDepartment of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany.
Alicia K MorgansDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michael J MorrisGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hind MrabtiNational Institute of Oncology, Mohamed V University, Rabat, Morocco.
Deborah MukherjiClemenceau Medical Center, Dubai, United Arab Emirates; Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Declan G MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Vedang MurthyTata Memorial Centre, Mumbai, India.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
William K OhDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Piet OstDepartment of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Joe M O'SullivanPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
Anwar R PadhaniMount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
Carmel PezaroSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Darren M C PoonComprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong; The Chinese University of Hong Kong, Shatin, Hong Kong.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Danny M RabahCancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, KFSHRC, Riyadh, Saudi Arabia.
Dana RathkopfGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert E ReiterUniversity of California Los Angeles, Los Angeles, CA, USA.
Mark A RubinBern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland.
Charles J RyanMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Fred SaadCentre Hospitalier de Université de Montréal, Montreal, Quebec, Canada.
Juan Pablo SadeInstituto Alexander Fleming, Buenos Aires, Argentina.
Oliver A SartorTulane Cancer Center, New Orleans, LA, USA.
Howard I ScherGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Nima SharifiDepartment of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
Iwona SkonecznaRafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
Howard SouleProstate Cancer Foundation, Santa Monica, CA, USA.
Daniel E SprattUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Sandy SrinivasDivision of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
Cora N SternbergEnglander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
Thomas SteuberMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Hiroyoshi SuzukiToho University Sakura Medical Center, Chiba, Japan.
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Mary-Ellen TaplinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
Levent TürkeriDepartment of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
Fabio TurcoOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
Hiroji UemuraYokohama City University Medical Center, Yokohama, Japan.
Hirotsugu UemuraDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Yüksel ÜrünDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey.
Claire L ValeUniversity College London, MRC Clinical Trials Unit at UCL, London, UK.
Inge van OortRadboud University Medical Center, Nijmegen, The Netherlands.
Neha VapiwalaDepartment of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Jochen WalzDepartment of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
Kosj YamoahDepartment of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Evan Y YuDepartment of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Almudena ZapateroDepartment of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
Thomas ZilliRadiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Aurelius OmlinOnkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland.
Ospedale Santa Chiara · ITUniversity College London · GBInstitute of Cancer Research · GBInstituto de Investigación Biomédica de Málaga · ESUniversity of Port Harcourt Teaching Hospital · NGUniversity of Washington · USMedical University of Vienna · ATSalford Royal Hospital · GBChinese University of Hong Kong · HKGuy's and St Thomas' NHS Foundation Trust · GBHospital Universitario 12 De Octubre · ESSheffield Teaching Hospitals NHS Foundation Trust · GBThe Royal Free Hospital · GBCopenhagen University Hospital · DKCornell University · USHong Kong Sanatorium and Hospital · HKInstitut Gustave Roussy · FRInstituto Alexander Fleming · ARMount Vernon Cancer Centre · GBRigshospitalet · DK

Funding

Department of HealthMedical Research Council MC_UU_00004/01Medical Research Council MC_UU_00004/02Medical Research Council MC_UU_00004/06Medical Research Council MR/W018217/1
6 · The paper itself

Abstract

backgroundInnovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.

objectiveTo present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND

participantsBefore the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis.

conclusionsThese voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleNeoplasm Recurrence, LocalAdjuvant therapyBiochemical recurrenceHormonal treatmentLocally advanced prostate cancerNext-generation imagingProstate cancerProstate-specific membrane antigen positron emission tomography imagingSalvage radiation therapySalvage therapySide effects

Identifiers

PMID36494221
PMCPMC7614721
OpenAlexW4311988438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.